Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) Net Income towards Common Stockholders (2024 - 2025)

Historic Net Income towards Common Stockholders for Kairos Pharma (KAPA) over the last 2 years, with Q2 2025 value amounting to -$1.4 million.

  • Kairos Pharma's Net Income towards Common Stockholders fell 50769.23% to -$1.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$5.2 million, marking a year-over-year change of. This contributed to the annual value of -$3.0 million for FY2024, which is 7158.31% down from last year.
  • Kairos Pharma's Net Income towards Common Stockholders amounted to -$1.4 million in Q2 2025, which was down 50769.23% from -$1.3 million recorded in Q1 2025.
  • In the past 5 years, Kairos Pharma's Net Income towards Common Stockholders ranged from a high of -$234000.0 in Q2 2024 and a low of -$1.6 million during Q4 2024